Research
Hormonal
GLP-1 receptor agonists (semaglutide and tirzepatide) are effective treatments for weight regain after bariatric surgery, producing clinically significant weight loss without severe adverse events.
If you regain weight after sleeve gastrectomy, GLP-1 medications like semaglutide or tirzepatide are effective and safe options to help you lose it back, avoiding the need for high-risk revisional surgery.
GoodSupportsHIGH confidence
In a retrospective cohort study of patients who underwent SG and sought treatment for weight recurrence, treatment with semaglutide and tirzepatide resulted in clinically significant mean weight losses of 10.3% and 15.5%, respectively, with no reported severe adverse events [97].
Why this rating
Cites specific retrospective cohort studies and phase 3 trials with clear numerical outcomes.
Source
Metabolic/bariatric surgery optimization: a position statement by Arabic association for the study of diabetes and metabolism (AASD)
Amin Roshdy Soliman et al. · Diabetology & Metabolic Syndrome · 2025
DOI 10.1186/s13098-024-01564-w
clinical_guidelineCited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Sleeve gastrectomy (SG) induces metabolic changes beyond restriction by reducing ghrelin and increasing GLP-1 and GIP, which stimulates insulin release and delays gastric emptying to improve type 2 diabetes.Good
- Sleeve gastrectomy is associated with a higher risk of new-onset or worsening gastroesophageal reflux disease (GERD) compared to Roux-en-Y gastric bypass (RYGB).Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →